Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.36 |
| ▸ | KRAS | P01116 | 2/20 | 0.36 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL129790 | 0.85 | ALDH1A1 (0.46) | KMT2AKDM4EALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL28999488 | 0.84 | PDCD1 (0.42) | SLC6A2SLC6A4SLC6A3KCNH2KDM4E | |
| SCHEMBL12648278 | 0.82 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3KCNH2KMT2A | |
| SCHEMBL16954651 | 0.81 | L3MBTL1 (0.40) | KDM4EALDH1A1SMN1; SMN2L3MBTL1PDCD1 | |
| SCHEMBL3860519 | 0.80 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3KCNH2KMT2A | |
| SCHEMBL14731944 | 0.80 | IDO1 (0.35) | KMT2AKDM4EALDH1A1SMN1; SMN2PDCD1 | |
| SCHEMBL19814847 | 0.80 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3KCNH2KMT2A | |
| SCHEMBL16390903 | 0.80 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3KCNH2KMT2A | |
| SCHEMBL7674619 | 0.80 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3KCNH2KMT2A | |
| SCHEMBL29912077 | 0.80 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3KCNH2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2900645-A1 | 3-PHENYLISOXAZOLIN DERIVATIVES WITH HERBICIDAL ACTION | Bayer CropScience AG (DE) | 2015-08-05 | — | — | EP | disclosed |
| US-8486943-B2 | Tetrahydrocyclopenta[b]indole androgen receptor modulators | ELI LILLY AND COMPANY (US) | 2013-07-16 | — | — | US | disclosed |
| US-8486943-B2 | Tetrahydrocyclopenta[b]indole androgen receptor modulators | ELI LILLY AND COMPANY (US) | 2013-07-16 | — | — | US | disclosed |
| US-8486943-B2 | Tetrahydrocyclopenta[b]indole androgen receptor modulators | ELI LILLY AND COMPANY (US) | 2013-07-16 | — | — | US | disclosed |
| US-8420646-B2 | Tricyclic tetrahydroquinoline antibacterial agents | PAH P&U LLC (US) | 2013-04-16 | — | — | US | disclosed |
| EP-2297100-B1 | TETRAHYDROCYCLOPENTA[B]INDOLE ANDROGEN RECEPTOR MODULATORS | LILLY CO ELI (US) | 2012-10-31 | — | — | EP | disclosed |
| EP-2297100-B1 | TETRAHYDROCYCLOPENTA[B]INDOLE ANDROGEN RECEPTOR MODULATORS | LILLY CO ELI (US) | 2012-10-31 | — | — | EP | disclosed |
| EP-1175400-B1 | RENIN INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-06-15 | — | — | EP | disclosed |
| US-20110092494-A1 | Tricyclic Tetrahydroquinoline Antibacterial Agents | PHARMACIA & UPJOHN COMPANY | 2011-04-21 | — | — | US | disclosed |
| EP-2297100-A1 | TETRAHYDROCYCLOPENTAÝB¨INDOLE ANDROGEN RECEPTOR MODULATORS | Eli Lilly & Company (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-1259512-B1 | PTERIDINE COMPOUNDS FOR THE TREATMENT OF PSORIASIS | ASTRAZENECA AB (SE) | 2003-09-24 | — | — | EP | disclosed |
| US-20030055250-A1 | Pteridine compounds for the treatment of psoriasis | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | US | disclosed |
| EP-1259512-A1 | PTERIDINE COMPOUNDS FOR THE TREATMENT OF PSORIASIS | AstraZeneca AB (SE) | 2002-11-27 | — | — | EP | disclosed |
| US-6476021-B1 | Compounds having cGMP-PDE inhibitory effect | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-05 | — | — | US | disclosed |
| US-20020087002-A1 | Naphthalenyl piperidines as renin inhibitors | NOVARTIS AG (CH) | 2002-07-04 | — | — | US | disclosed |
| US-6376672-B1 | RESTENOSIS; VISION DEFECTS; CARDIOVASCULAR DISORDERS; KIDNEY DIEASES | HOFFMANN-LA ROCHE INC. | 2002-04-23 | — | — | US | disclosed |
| EP-1175400-A1 | RENIN INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-30 | — | — | EP | disclosed |
| WO-2001062758-A1 | PTERIDINE COMPOUNDS FOR THE TREATMENT OF PSORIASIS | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
| WO-2000064873-A1 | RENIN INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-11-02 | — | — | WO | disclosed |
| EP-1048666-A1 | NOVEL COMPOUNDS HAVING cGMP-PDE INHIBITORY EFFECT | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092494-A1 | Tricyclic Tetrahydroquinoline Antibacterial Agents | QTRT1, QTRT2, NQO2 | SLC6A2 2511/4885SLC6A4 2611/4885SLC6A3 2915/4885 |
| US-20020087002-A1 | Naphthalenyl piperidines as renin inhibitors | REN, TNNI3, PTGIS | SLC6A2 2088/4885SLC6A4 2337/4885SLC6A3 2151/4885 |
| US-20030055250-A1 | Pteridine compounds for the treatment of psoriasis | DHFR, NAMPT, HPRT1 | SLC6A2 3869/4885SLC6A4 4108/4885SLC6A3 4688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.